Can an arthritis drug tame brain inflammation in Alzheimer's and ALS?
NCT ID NCT05189106
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-phase study tested the drug baricitinib in 17 people with Alzheimer's disease, ALS, or mild cognitive problems. The goal was to see if the drug reaches the brain and lowers inflammation linked to these diseases. Participants took baricitinib pills for 24 weeks, and researchers measured drug levels and inflammatory markers in spinal fluid.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital - AD Site
Charlestown, Massachusetts, 02129, United States
-
Massachusetts General Hospital - ALS Site
Boston, Massachusetts, 02129, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Could your brain help unlock Alzheimer's secrets?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a Voice-Based app map healthy brain aging across 80 years?